跳至主要内容
临床试验/JPRN-jRCTs061180062
JPRN-jRCTs061180062进行中(未招募)3 期

The efficacy of reduced form of coenzyme Q10 in the Treatment of dementia - The efficacy of reduced form of coenzyme Q10 in the Treatment of dementia

ABE SATOSHI0 个研究点目标入组 100 人开始时间: 2019年3月18日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 50age old 至 <= 89age old(—)
性别
All

入选标准

  • 1)Diagnosis is one of five types of dementia.
  • Alzheimer disease, Vascular dementia, Dementia of Lewy Body, frontotemporal dementia, Mild Cognitive Impairment: (MCI)
  • 2)Clinical Dementia Rating (CDR) is 0.5,1 or 2 (mild-moderate dementia).
  • 3)Mini-Mental State Examination (MMSE) score is between 15 and 28.
  • 4)Treatment has been kept with four drugs, donepezil, galantamine, rivastigmine, memantine and some other drug.
  • 5)Agreement with clinical trial is between 50 and 89 years old.
  • 6)A declaration of consent shall be valid if drawn up as a document providing sufficient evidence.

排除标准

  • 1)Metabolic encephalopathy (hypothyroidism, Vitamin B12 deficiency)
  • 2)Post head trauma
  • 3)Delirium due to any drugs
  • 4)Alcohol abuse
  • 5)Depression under medication
  • 6)Mental disorder treated by antipsychotic drugs
  • 7)Schizophrenia, mania, severe heart failure, and severe liver injury.
  • 8)Chronic renal failure with creatinine clearance less than 20 ml/min.
  • 9)Treated with malignancy
  • 10) Investigator decides inappropriate for enrollment

研究者

发起方
ABE SATOSHI

相似试验